Brian Leyland‐Jones
- Oncology top 0.05%
- Molecular Biology top 1%
- Cancer Research top 0.1%
- Radiology, Nuclear Medicine and Imaging top 0.1%
- Pulmonary and Respiratory Medicine top 0.5%
- Co-authors
- Dennis J. SlamonJosé BaselgaMark D. PegramSteven ShakW. EiermannVirginia PatonLarry NortonAlex Bajamonde
- Topics
- HER2/EGFR in Cancer Research (50 papers)Cancer Treatment and Pharmacology (29 papers)Cancer Genomics and Diagnostics (28 papers)
- Partner nations
- United StatesCanadaItaly
In The Last Decade
Brian Leyland‐Jones
214 papers receiving 17.9k citations
Hit Papers
Peers
Comparison fields: 5 of 156
- Oncology 11.6k
- Molecular Biology 5.7k
- Cancer Research 4.6k
- Radiology, Nuclear Medicine and Imaging 4.1k
- Pulmonary and Respiratory Medicine 3.3k
Countries citing papers authored by Brian Leyland‐Jones
This map shows the geographic impact of Brian Leyland‐Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Leyland‐Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Leyland‐Jones more than expected).
Fields of papers citing papers by Brian Leyland‐Jones
This network shows the impact of papers produced by Brian Leyland‐Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Leyland‐Jones. The network helps show where Brian Leyland‐Jones may publish in the future.
Co-authorship network of co-authors of Brian Leyland‐Jones
This figure shows the co-authorship network connecting the top 25 collaborators of Brian Leyland‐Jones. A scholar is included among the top collaborators of Brian Leyland‐Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Leyland‐Jones. Brian Leyland‐Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 15 | |
| 2 | 90 | |
| 3 | 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialbreakdown → | 688 |
| 4 | 3 | |
| 5 | 21 | |
| 6 | 1 | |
| 7 | 30 | |
| 8 | 74 | |
| 9 | 77 | |
| 10 | 18 | |
| 11 | 45 | |
| 12 | Response of breast cancer cell lines to aminoflavone (NSC 686288) is associated with histone H2AX phosphorylation and estrogen receptor expression | 4 |
| 13 | Mammalian Target of Rapamycin Inhibition Synergistically Increases Cytotoxicity of Vinorelbine in Breast Cancer Cells. | 1 |
| 14 | 342 | |
| 15 | Reversal of multidrug resistance by Pluronic block copolymers correlates with inhibition of drug efflux transporters and depletion of intracellular ATP and GSH levels. | 1 |
| 16 | Treating cancer-related hypercalcemia with gallium nitrate. | 14 |
| 17 | 130 | |
| 18 | 17 | |
| 19 | 14 | |
| 20 | 4 |
About Brian Leyland‐Jones
Brian Leyland‐Jones is a scholar working on Cancer Research, Oncology and Hematology, having authored 218 papers that have together received 18.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (50 papers), Cancer Treatment and Pharmacology (29 papers) and Cancer Genomics and Diagnostics (28 papers). The work is most often cited by research in Oncology (11.6k citations), Cancer Research (4.6k citations) and Radiology, Nuclear Medicine and Imaging (4.1k citations). Brian Leyland‐Jones has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Dennis J. Slamon, José Baselga, Mark D. Pegram, Steven Shak, W. Eiermann, Virginia Paton, Larry Norton, Alex Bajamonde, Thomas Fleming and Janet Wolter. Their work appears in journals such as New England Journal of Medicine, The Lancet and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.